| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy [G. G., C. C., E. G., M. P. C.]; Department of Experimental Medicine and Pathology, 2nd Chair of Pathology, University of Rome "La Sapienza," 00161 Rome, Italy [A. S.]; and Department of Immunology and Bacteriology, University of Glasgow, Glasgow G11 6NT, United Kingdom [F. Y. L.]
IFN-
knockout mice (GKO) rejected C26 colon carcinoma cells transduced to secrete interleukin(IL)-12 but do not reject similarly transduced TSA mammary adenocarcinoma (C26/12 and TSA/12 cells, respectively). To determine whether such difference could be because of a different tumor response to IFN-, we injected BALB/c mice with TSA, C26, and their IL-12-transduced counterparts rendered unresponsive to IFN- by stable transduction of a dominant negative (DN), truncated IFN- receptor 
chain. TSA/DN and C26/DN showed the same in vivo growth kinetics as parental cells, whereas coexpression of IL-12 induced rejection independent of tumor-cell responsiveness to IFN-. This suggests that the role of IFN- is primarily in activating the host immune response, which appears to depend on the intrinsic immunogenicity of the target tumor. C26 and TSA share a common tumor-associated antigen, yet C26 cells are more immunogenic than TSA. C26/12 expressed 10-fold higher levels of class I MHC molecules and induced higher CTL activity compared with TSA/12 cells in GKO mice. Moreover, whereas in GKO mice the TSA/12 tumor was associated with a greater number of infiltrating T cells, only those infiltrating C26/12 tumor expressed the activation marker OX40. The search for cytokine(s) that might contribute in determining the different T-cell response to these IL-12-transduced tumors in GKO mice revealed a role of IL-15. In situ hybridization showed IL-15 expression in C26/12 but not in TSA/12 tumors. In addition, injection of GKO mice with soluble IL-15 receptor- to block IL-15 expression prevented rejection of C26/12 cells. Together, the results suggest that in the absence of IFN-, IL-12 can exert antitumor activity through alternative mechanisms, depending on the tumor cell type and the availability of cytokines that can replace IFN- in sustaining T-cell functions.
This article has been cited by other articles:
|
|
 |
|
  M. Numasaki, M. Tagawa, F. Iwata, T. Suzuki, A. Nakamura, M. Okada, Y. Iwakura, S. Aiba, and M. Yamaya IL-28 Elicits Antitumor Responses against Murine Fibrosarcoma J. Immunol., April 15, 2007; 178(8): 5086 - 5098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mortara, P. Castellani, R. Meazza, G. Tosi, A. De Lerma Barbaro, F. A. Procopio, A. Comes, L. Zardi, S. Ferrini, and R. S. Accolla CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory. Clin. Cancer Res., June 1, 2006; 12(11): 3435 - 3443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Comes, O. Rosso, A. M. Orengo, E. Di Carlo, C. Sorrentino, R. Meazza, T. Piazza, B. Valzasina, P. Nanni, M. P. Colombo, et al. CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine J. Immunol., February 1, 2006; 176(3): 1750 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Lin, R. Lai, L. R. Chirieac, C. Li, V. A. Thomazy, I. Grammatikakis, G. Z. Rassidakis, W. Zhang, Y. Fujio, K. Kunisada, et al. Constitutive Activation of JAK3/STAT3 in Colon Carcinoma Tumors and Cell Lines: Inhibition of JAK3/STAT3 Signaling Induces Apoptosis and Cell Cycle Arrest of Colon Carcinoma Cells Am. J. Pathol., October 1, 2005; 167(4): 969 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Croce, R. Meazza, A. M. Orengo, L. Radic', B. De Giovanni, C. Gambini, B. Carlini, V. Pistoia, L. Mortara, R. S. Accolla, et al. Sequential Immunogene Therapy with Interleukin-12- and Interleukin-15-Engineered Neuroblastoma Cells Cures Metastatic Disease in Syngeneic Mice Clin. Cancer Res., January 15, 2005; 11(2): 735 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Koka, P. Burkett, M. Chien, S. Chai, D. L. Boone, and A. Ma Cutting Edge: Murine Dendritic Cells Require IL-15R{alpha} to Prime NK Cells J. Immunol., September 15, 2004; 173(6): 3594 - 3598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Guiducci, E. Di Carlo, M. Parenza, M. Hitt, M. Giovarelli, P. Musiani, and M. P. Colombo Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor J. Immunol., April 1, 2004; 172(7): 4026 - 4036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Shi, S. Cao, M. Mitsuhashi, Z. Xiang, and X. Ma Genome-Wide Analysis of Molecular Changes in IL-12-Induced Control of Mammary Carcinoma via IFN-{gamma}-Independent Mechanisms J. Immunol., April 1, 2004; 172(7): 4111 - 4122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Di Carlo, A. Comes, A. M. Orengo, O. Rosso, R. Meazza, P. Musiani, M. P. Colombo, and S. Ferrini IL-21 Induces Tumor Rejection by Specific CTL and IFN-{gamma}-Dependent CXC Chemokines in Syngeneic Mice J. Immunol., February 1, 2004; 172(3): 1540 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kuniyasu, H. Ohmori, T. Sasaki, T. Sasahira, K. Yoshida, Y. Kitadai, and I. J. Fidler Production of Interleukin 15 by Human Colon Cancer Cells Is Associated with Induction of Mucosal Hyperplasia, Angiogenesis, and Metastasis Clin. Cancer Res., October 15, 2003; 9(13): 4802 - 4810. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
